ORKA Oruka Therapeutics, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Clinical-stage biopharma developing novel monoclonal antibodies for psoriasis and inflammatory/immunology indications
• • New emphasis: Acquisition and rebranding of Pre-Merger Oruka in 2024, launching dual lead programs ORKA-001 and ORKA-002 targeting IL-23p19 and IL-17A/F

Risk Factors

• • FDA regulatory delays risk impacting approval timeline for product candidates ORKA-001 and ORKA-002 amid ongoing Phase 1 and Phase 2 trials
• • Geopolitical tensions and elevated interest rates contributing to market volatility that may hinder timely capital raises for ongoing clinical development

Management Discussion & Analysis

• • No revenue generated; net loss $105.4M for 2025; accumulated deficit $189.2M as of December 31, 2025
• • Operating cash flow negative $88.2M; cash, equivalents, and marketable securities $479.6M at year-end

Risk Factors

• • New risk: At-the-market equity offering program up to $200M initiated in Oct 2025 to raise capital amid market volatility and regulatory uncertainty
• • Updated risk: Clinical trial delays and potential increased costs highlighted due to slow enrollment and third-party contractor noncompliance risks

What are the latest ORKA SEC filings in 2026?

Oruka Therapeutics, Inc. (ORKA) has filed a 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 12, 2025, an 8-K current report on April 30, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did ORKA file its most recent 10-K annual report?

Oruka Therapeutics, Inc. (ORKA) filed its most recent 10-K annual report on March 12, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view ORKA 10-Q quarterly reports?

Oruka Therapeutics, Inc. (ORKA)'s most recent 10-Q quarterly report was filed on November 12, 2025. SignalX displays every ORKA 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has ORKA filed recently?

Oruka Therapeutics, Inc. (ORKA)'s most recent 8-K was filed on April 30, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find ORKA insider trading activity (Form 4)?

SignalX aggregates every ORKA Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does ORKA file with the SEC?

Oruka Therapeutics, Inc. (ORKA) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new ORKA filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Oruka Therapeutics, Inc. (ORKA).

What is ORKA's SEC CIK number?

Oruka Therapeutics, Inc. (ORKA)'s SEC CIK (Central Index Key) number is 907654. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 907654 to look up all ORKA filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find ORKA return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Oruka Therapeutics, Inc. (ORKA) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.